Simvastatin restores down-regulated gata-6 expression in pulmonary hypertensive Rats

Experimental Lung Research

Volumn 35, Issue 5, 2009, Pages 411-426

  Liu, Bin ^a   Wang, Xiao Qin ^a   Yu, Li ^a   Zhou, Tong Fu ^a   Wang, Xian Min ^a   Liu, Han Min ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Pulmonary hypertension; Statins; Transcription factor; Vascular remodeling

Indexed keywords

MESSENGER RNA; SIMVASTATIN; TRANSCRIPTION FACTOR GATA 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG RESECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GATA6 TRANSCRIPTION FACTOR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MONOCROTALINE; PNEUMONECTOMY; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; TIME FACTORS;

EID: 70849120960     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140902736819     Document Type: Article

References (56)

1. Budhiraja R, Tuder RM, Hassoun PM: Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165.
2. Botney MD: Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:361-364.
3. van Albada ME, Schoemaker RG, Kemna MS, et al: The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J. 2005;26:487-493.
4. Stenmark KR, Mecham RP: Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol. 1997;59:89-144.
5. Sokabe T, Yamamoto K, Ohura N, et al: Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287:H2027-H2034.
6. Davies PF: Flow-mediated endothelial mechanotransduction. Physiol Rev. 1995;75:519-560.
7. Orkin SH: GATA-binding transcription factors in hematopoietic cells. Blood. 1992;80:575-581.
8. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000;275:38949-38952.
9. Ting CN, Olson MC, Barton KP, et al: Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996;384:474-478.
10. Tsai FY, Keller G, Kuo FC, et al: An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994;371:221-226.
11. De Maria R, Zeuner A, Eramo A, et al: Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999;401:489-493.
12. Orkin SH, Shivdasani RA, Fujiwara Y, et al: Transcription factor GATA-1 in megakaryocyte development. Stem Cells. 1998;16(Suppl 2):79-83.
13. Patient RK, McGhee JD: The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev. 2002;12:416-422.
14. Yang H, Lu MM, Zhang L, et al: GATA6 regulates differentiation of distal lung epithelium. Development 2002;129:2233-2246.
15. Morrisey EE, Ip HS, Lu MM, et al: GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309-322.
16. Fischer A, Klattig J, Kneitz B, et al: Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol. 2005;25:8960-8970.
17. Zhao R, Watt AJ, Li J, et al: GATA6 is essential for embryonic development of the liver but dispensable for early heart formation. Mol Cell Biol. 2005;25:2622-2631.
18. Suzuki E, Evans T, Lowry J, et al: The human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals. Genomics 1996;38:283-290.
19. Perlman H, Suzuki E, Simonson M, et al: GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest. J Biol Chem. 1998;273:13713-13718.
20. Mano T, Luo Z, Malendowicz SL, et al: Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ Res. 1999;84:647-654.
21. Morrisey EE: GATA-6: the proliferation stops here: cell proliferation in glomerular mesangial and vascular smooth muscle cells. Circ Res. 2000;87:638-640.
22. Sokabe T, Yamamoto K, Ohura N, et al: Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287:H2027-H2034.
23. Lepore JJ, Cappola TP, Mericko PA, et al: GATA-6 regulates genes promoting synthetic functions in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:309-314.
24. Mishra TK, Routray S: Current perspectives on statins. J Indian Med Assoc. 2003;101:381-383.
25. Kwak B, Mulhaupt F, Myit S, et al: Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
26. Bustos C, Hernandez-Presa MA, Ortego M, et al: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
27. Indolfi C, Cioppa A, Stabile E, et al: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35:214-221.
28. Laufs U, Marra D, Node K, et al: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
29. Laufs U, Fata VL, Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729.
30. Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
31. Nishimura T, Vaszar LT, Faul JL, et al: Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation JT - Circulation. 2003;108:1640-1645.
32. Nishimura T, Faul JL, Berry GJ, et al: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166:1403-1408.
33. Girgis RE, Li D, Zhan X, et al: Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003;285:H938-H945.
34. Wada H, Abe M, Ono K, et al: Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun. 2008;374:731-736.
35. Okada K, Tanaka Y, Bernstein M, et al: Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol. 1997;151:1019-1025.
36. Faul JL, Nishimura T, Berry GJ, et al: Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2000;162:2252-2258.
37. Nishimura T, Faul JL, Berry GJ, et al: 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2001;163:498-502.
38. Hoshikawa Y, Ono S, Suzuki S, et al: Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol. 2001;90:1299-1306.
39. Fishman AP, FishmanMC, Freeman BA, et al: Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med. 1998;158:670-674.
40. Newman JH, Lane KB: Hypertensive pulmonary vascular disease: dawn of the age of prevention?. Am J Respir Crit Care Med. 2000;162:2020-2021.
41. Kao PN, Faul JL: Emerging therapies for pulmonary hypertension: striving for efficacy and safety. J Am Coll Cardiol. 2003;41:2126-2129.
42. Rubin LJ: Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002;166:1308-1309.
43. Newman JH, Fanburg BL, Archer SL, et al: Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004;109:2947-2952.
44. Chan AW, Bhatt DL, Chew DP, et al: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
45. Heeschen C, Hamm CW, Laufs U, et al: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
46. Epstein M, Campese VM: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2-14.
47. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev. 2001;81:153-208.
48. Rikitake Y, Liao JK: Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97:1232-1235.
49. Stark WW Jr, Blaskovich MA, Johnson BA, et al: Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 1998;275(1 Pt 1):L55-L63.
50. Hernandez-Perera O, Perez-Sala D, Soria E, et al: Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000;87:616-622.
51. Xu CB, Stenman E, Edvinsson L: Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002;64:497-505.
52. Kalinowski L, Dobrucki LW, Brovkovych V, et al: Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002;105:933-938.
53. Weissmann N, Winterhalder S, Nollen M, et al: NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol. 2001;280:L638-L645.
54. Sun-Wada GH, Kamei Y, Wada Y, et al: Regulatory elements directing gut expression of the GATA6 gene during mouse early development. J Biochem (Tokyo) 2004;135:165-169.
55. Narita N, Heikinheimo M, Bielinska M, et al: The gene for transcription factor GATA-6 resides on mouse chromosome 18 and is expressed in myocardium and vascular smooth muscle. Genomics 1998;36:345-348.
56. Arora M, Chen L, Paglia M, et al: Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A, 2006;103:7777-7782.